Kidney Contenders®

We learn. We evolve. Our view is the kidney, but we contend for overall well-being. #healthwellness

[Kidney Contenders® @KidneyContender]

Join our early‑supporter test on Android 📱✨
Help us build tools that empower kidney patients 💪🧡 Tap the link to become a tester 🔗⬆️
https://t.co/J3c9j460Eu

[Kidney Contenders® @KidneyContender]

@CDCgov Lifestyle matters, but so do the stressors people can’t control. Clear guidance, supportive environments, and accessible prevention pathways make it easier for patients to lower stroke risk. Prevention works best when the system reduces avoidable stress.

[Kidney Contenders® @KidneyContender]

@society_eas Early FH detection is one of the strongest tools we have to reduce lifelong LDL exposure. Paediatric screening—done thoughtfully and aligned with local resources—can make a real difference in long‑term cardiovascular risk. Prevention starts early.

[Kidney Contenders® @KidneyContender]

@Surgeon_General @SecKennedy @HHSGov Prevention efforts for tick‑borne illnesses are urgently needed. Clear guidance, early detection, and community awareness can make a real difference. It’s encouraging to see attention on conditions that often go unnoticed until they become serious.

[Kidney Contenders® @KidneyContender]

@ClevelandClinic Protecting brain health starts with prevention and early awareness. Clear guidance on risks, lifestyle factors, and screening can make a real difference over time. Empowering people with information is one of the strongest tools we have.

[Kidney Contenders® @KidneyContender]

@JAMACardio ANOCA is a reminder that “normal” arteries don’t rule out significant symptoms. Overlapping endotypes make diagnosis and management more complex, so clear testing pathways and patient communication are essential for reducing angina burden.

[Kidney Contenders® @KidneyContender]

@worldkidneyday Asking questions is one of the strongest tools patients have. Clear conversations about risk factors and the right tests make early detection possible. Prevention works best when people feel confident navigating their kidney health.

[Kidney Contenders® @KidneyContender]

@Medscape Weight regain after GLP‑1 discontinuation isn’t surprising when cost, side effects, and coverage gaps drive early drop‑off. Real‑world outcomes improve when patients have clear guidance, sustainable plans, and support beyond the medication alone.

[Kidney Contenders® @KidneyContender]

@Heart_BMJ Screening for AFib is one of the clearest examples of how early detection can change long‑term outcomes. The challenge isn’t just the technology — it’s making sure screening pathways are clear, accessible, and easy for patients to navigate.

[Kidney Contenders® @KidneyContender]

@TheTXVoice Public safety matters to all of us, but any statewide prosecutor model needs clear guardrails, transparency, and coordination with local systems. Texans deserve solutions that improve safety without creating new gaps or confusion.

[Kidney Contenders® @KidneyContender]

Prevention care is supposed to be simple.
But unclear calls, confusing workflows, and poor communication push people away.

People don’t skip prevention because they don’t care — they skip it because the system makes it hard.

#PreventionCare #HealthLiteracy #KidneyContenders

[Kidney Contenders® @KidneyContender]

@TheLancet @ERAkidney The global CKD burden is staggering — and still rising. The Series is a needed push toward earlier detection, upstream risk reduction, and stronger health‑system coordination. Changing this trajectory means treating CKD as the major public‑health priority it is.

[Kidney Contenders® @KidneyContender]

@EuroInterventio Great overview of the key touchpoints in TAVI + coronary work. Physiology, PCI timing, re‑access, and obstruction prevention all matter more as lifetime management becomes the norm. Helpful synthesis for real‑world structural workflows.

[Kidney Contenders® @KidneyContender]

@DrFrankLipman The flavonoid story keeps pointing back to the same theme: oxidative stress and inflammation sit upstream of many age‑related conditions. Interesting to see how compounds like apigenin interact with those pathways at the cellular level.

[Kidney Contenders® @KidneyContender]

@JAMA_current MCED tests are promising, but the key question is still clinical utility: earlier stage detection vs earlier within‑stage detection. Sensitivity, specificity, and downstream pathways matter as much as the number of cancers screened.

[Kidney Contenders® @KidneyContender]

@ZainKhalpey TDI is such a valuable early‑signal tool. S′, E′, and A′ often reveal subtle ventricular dysfunction long before global metrics shift. Great reminder of how much nuance lives in tissue velocities.

[Kidney Contenders® @KidneyContender]

@WebMD Oats are one of those foods that quietly do a lot of heavy lifting—fiber, steady energy, and cardiometabolic support. Always interesting to see how versatile they are beyond breakfast.

[Kidney Contenders® @KidneyContender]

@DrDaleBredesen The inflammation link keeps showing up across studies. Serious infections raising long‑term dementia risk fits the broader pattern: immune stress today can shape cognitive vulnerability years later. Another reminder that early detection + prevention matter.

[Kidney Contenders® @KidneyContender]

@Medscape Nonsteroidal MRAs are becoming a key lever in CKM care, especially for patients with overlapping CV, kidney, and metabolic risk. Helpful to see guidance that connects the evidence to real‑world, team‑based management.

[Kidney Contenders® @KidneyContender]

@CDCgov Important reminder from CDC: stroke risk isn’t limited by age. The encouraging part is how much risk can drop with consistent habits around BP, activity, nutrition, and avoiding tobacco. Small changes compound over time to #StopStroke.

[Kidney Contenders® @KidneyContender]

@drbennisahmed The BMI signal is interesting, but the inflammation signal is the real driver. Obesity + elevated hsCRP marks a high‑risk phenotype that sees outsized benefit from intensive LDL‑C lowering. That ≥30 + hsCRP >3 subgroup reinforces that risk biology > weight alone.